| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $143K | -86.1% | — |
| R&D Expense | $90.5M | +12.7% | +46.1% |
| SG&A Expense | $52.3M | +4.9% | +101.9% |
| Operating Income | -$142.6M | -10.4% | -62.4% |
| Pre-tax Income | -$130.1M | — | -69.3% |
| Net Income | -$130.1M | -12.5% | -69.3% |
| EPS (Basic) | -$1.38 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $110.9M | +106.4% | -65.0% |
| Short-term Investments | $981.4M | -14.1% | +79.9% |
| Current Assets | $1.12B | -7.9% | +27.8% |
| Total Assets | $1.20B | -7.3% | +27.6% |
| Current Liabilities | $74.2M | +8.4% | +38.4% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$285.0M | — | — |
| Capital Expenditures | $5.3M | — | — |
| Investing Cash Flow | $116.8M | — | — |
| Financing Cash Flow | $14.6M | — | — |
| Free Cash Flow | -$290.3M | — | — |
| -43.7% |
| EPS (Diluted) | -$1.38 | -12.2% | -43.7% |
| $123.9M |
| +4.9% |
| +18.6% |
| Stockholders' Equity | $1.07B | -8.5% | +28.7% |